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Abstract 
Background 
Ovarian suppression in premenopausal women is known to reduce breast cancer risk. This study 
aimed to assess uptake and compliance with ovarian suppression using the LHRH analogue, 
goserelin, with add-back raloxifene, as a potential regimen for breast cancer prevention. 
 
Methods 
Women at ≥30% lifetime risk breast cancer were approached and randomized to 
mammographic screening alone(C-Control) or screening in addition to monthly subcutaneous 
injections of 3.6mg goserelin and continuous 60mg raloxifene daily orally(T-Treated) for two-
years. The primary endpoint was therapy adherence. Secondary end points were toxicity/quality 
of life, change in bone density and mammographic density.  
 
Results  
75/950 (7.9%) women approached agreed to randomization. In the T-arm, 20/38 (52%) of 
women completed the two-year period of study compared with the C-arm (27/37, 73.0%).  
Drop-outs were related to toxicity but also the wish to have established risk-reducing 
procedures and proven chemoprevention. As relatively few women completed the study, data 
are limited, but those in the T-arm reported significant increases in toxicity and sexual problems, 
no change in anxiety and less cancer worry.  Lumbar spine bone density declined by 7.0 % and 
visually assessed mammographic density by 4.7% over the two-year treatment period. 
 
Conclusion 
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Uptake is somewhat lower than comparable studies with tamoxifen for prevention with higher 
drop-out rates. Raloxifene may preserve bone density but reduction in mammographic density 
reversed after treatment was completed. 
 
Impact 
This study indicates that breast cancer risk reduction may be possible using LHRH agonists, but 
reducing toxicity and preventing bone changes would make this a more attractive option.  
 
 
 
 
Introduction  
 
Observational studies of women who undergo premenopausal bilateral oophorectomy, both in 
the general population and in the majority of studies in those with inactivating mutations in the 
BRCA1 and BRCA2 genes, have a reduction in breast cancer risk of as much as 50% with a 
greater effect the younger the age of operation (1, 2, 3, 4, 5, 6, 7).  
 
Surgical oophorectomy was widely used as a breast cancer treatment, but clinical trials  
indicated that surgery could be replaced by the use of either intranasal or subcutaneous 
administration of luteinizing hormone releasing hormone (LHRH) agonists for breast cancer 
treatment (8,9T). Recently it has been shown that combining treatment with the LHRH agonist 
goserelin increased the effectiveness of adjuvant tamoxifen in premenopausal women with 
breast cancer (10) 
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In 1989 Pike and his colleagues (11) suggested that LHRH analogues might be used for the 
prevention of breast cancer primarily by the reduction of cyclical ovarian hormones. 
Subsequently this group reported two small trials exploring this approach where toxicity was 
reduced by add-back oestrogen, medoxyprogesterone acetate and testosterone (12,13). 
 
In order to develop this approach to prevention in women at high risk of breast cancer we 
designed three randomized trials of treatment with the LHRH agonist goserelin were designed 
with different add-back regimens (raloxifene, tibolone or ibandronate). The primary aims of 
these studies were to assess uptake of and adherence to treatment with secondary aims of 
assessing toxicity/quality of life, bone density and mammographic density. The results using 
add-back ibandronate were reported previously (14). We now report the study with add-back 
raloxifene (previously reported in abstract form (15). The trial with tibolone was not initiated 
because of ethical issues in Holland (Klijn, personal communication). 
 
 
Participants and methods 
Study design 
This was an open-label phase II, randomised trial which compared screening by mammography 
plus treatment with goserelin and raloxifene (T-arm) with screening by mammography only (C-
arm). The initial protocol included only women with ≥40% lifetime risk of breast cancer but was 
amended to include ≥30% risk because of slow recruitment. Women between the ages of 30 and 
46 years with normal ovarian function and high risk of familial breast cancer (≥30% lifetime risk) 
were invited to participate in the RAZOR (RAloxifene and ZOladex Research Study) trial in 
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Manchester, London and Southampton, all in the UK. Treatment was subcutaneous goserelin, 
3.6 mg once every 4 weeks (supplied by Astrazeneca UK), and raloxifene, 60mg orally daily 
(supplied by Lilly), both for 2-years. Delays in treatment visits were recorded. No dose or 
schedule modifications were permitted.  
Approvals from the three relevant ethics committees were obtained and the study was 
conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. 
Each participant gave written informed consent before randomisation. The trial number is 
NCT00031850. 
Patient Eligibility 
All participants were required to use non-hormonal contraception and have an estimated life 
expectancy of more than 10-years. Women with the following were excluded: current 
pregnancy or planning a pregnancy in the next 2-years, lactation, current treatment with 
anticoagulants, history of deep vein thrombosis or pulmonary embolism, being postmenopausal, 
mastectomy or bilateral oophorectomy and no prior history of breast cancer or other invasive 
malignancy except basal cell carcinoma or in situ cervix or basal cell carcinoma. 
Endpoints 
The primary endpoint of the trial was compliance with adherence to treatment. Secondary 
endpoints were:  occurrence of toxicity and change in impact on quality of life, change in bone 
mineral density and change in serum lipids. 
Toxicity and quality of life 
Toxicity and quality of life were assessed using four standardised patient reported outcome 
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measures (FACT-Endocrine Subscale [ES], Sexual Activity Questionnaire [SAQ], the State-Trait 
Anxiety Inventory [STAI] and the Cancer Worry Scale [CWS] given at baseline and one month 
and three monthly from baseline for 2 years.  
The FACT-ES comprises 20 items: (I have) hot flushes, cold sweats, night sweats, vaginal 
discharge, vagina itching/irritation, vaginal bleeding or spotting, vaginal dryness, pain or 
discomfort with intercourse, lost interest in sex, gained weight, light-headed/dizzy, vomiting, 
diarrhea, headaches, bloated, breast sensitivity/tenderness, mood swings, irritable, lack of 
energy, nausea. Respondents state how bothered they have been over the previous 7 days using 
Likert type categorical scoring: not at all, 1; somewhat, 2; moderately, 3; and very much, 4. The 
overall ES score is the sum of 20 single scores between 0 and 4 thus total scores ranged from 0 
to 80. As negatively framed questions are reversed higher scores correspond to a less severe 
symptoms and better QoL (16). The Sexual Activity Questionnaire (SAQ) is a validated self-report 
questionnaire divided into 2 sections: 1) a screening section to establish whether or not the 
patient is sexually active, and reasons for sexual inactivity if appropriate, 2) 10 items regarding 
sexual functioning 17). The Speilberger State/Trait Anxiety Inventory (STAI) has 20 items: (I 
feel/am) calm, secure, tense, strained, at ease, upset, worrying over misfortune, satisfied, 
frightened, comfortable, self-confident, nervous, jittery, indecisive, relaxed, content, worried, 
confused, steady, and pleasant. Respondents use Likert-type categorical scoring: not at all, 1; 
somewhat, 2; moderately, 3; and very much, 4. An overall anxiety score is the sum of 20 single 
scores (range 20 to 80). Higher scores correspond to higher anxiety (18). The CWS (19) is a six 
item scale designed to measure worry about the risk of developing cancer and the impact of 
worry on daily functioning. The scores were: 1, rarely or never; 2, sometimes; 3, often; 4, all the 
time. The overall score is a range from 6 to 24. 
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Patients also completed study specific exit interviews. 
Standard laboratory methodology was used to measure serum progesterone, SHBG , CTX and 
lipids. Serum oestradiol levels were measured using a highly sensitive assay (detection limit 
3pmol/l), as previously described (20). 
Bone density  
Bone mineral density (BMD) was measured at the lumbar spine, femoral neck, and total hip 
using a Hologic scanner and was reported as gm/cm2, T- and Z-scores. The scanner was 
calibrated daily with a spine phantom to ensure all measurements were reliable.  Reports were 
obtained from the Department of Clinical Radiology, Imaging Science and Biomedical 
Engineering, University of Manchester. 
Mammographic density   
Breast density was assessed using a visual assessment score (VAS) as previously described (21, 
22) This was formed by taking the mean percent density that was assessed by two radiologists 
who scored up to 4 mammographic views from each visit by eye.  
Statistical considerations 
Blinding was not possible since it was not considered ethical to give placebo monthly injections, 
and the onset of amenorrhoea would amount to unblinding. Randomization was performed 
centrally at the Centre for Cancer Prevention, London. Stratification occurred within each 
participating institution. Analyses were conducted on an intent-to-treat basis. All participants 
who were randomized and received treatment or screening were evaluated by treatment arm.  
Nonparametric methods were employed for analysis due to small numbers in the study.  The χ2 
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test was used to compare nominal data, and Fisher’s Exact test was used for 2 x 2 tables.  P 
values must be interpreted with caution due to the small numbers compared.  Missing or 
inapplicable measures were excluded when calculating P values. P values in the tables refer to 
the comparison of only those with measures at the correct time points. Differences in 
mammographic density between the two arms were assessed using a linear mixed model (see 
supplementary material), and a non-parametric bootstrap for mean density differences between 
time points. In the quality of life analyses the majority of total scores were not normally 
distributed, therefore non-parametric Mann-Whitney and Wilcoxon tests were used and, 
because of multiple testing significance, was taken as a P value of <0.01. 
Results 
Baseline characteristics 
 
Between June 2000 and March 2004, 75 invited women agreed to be randomised in the trial 
(Figure 1-shows a consort diagram).  Women were seen face to face, but were also sent a mail 
shot. Initially 32 women at the originally protocolled ≥40% risk were recruited in Manchester 
from 601 eligible women (5.2%). The risk threshold was reduced to ≥30% because of slow 
recruitment. Overall, at least 950 women were contacted in order to recruit the final 75 women, 
giving an uptake of at most 7.9% (Figure 1). The reasons for non-participation were assessed in a 
subset of 89 women. Fear of side effects (81%), wish to wait to join a projected larger study 
(48%), concern about the possibility of permanent amenorrhoea (32%), no time (30%) and 
dislike of pills (16%) were the major reasons for non-entry. No woman declined because of the 
randomisation process. 
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Characteristics of women who agreed to randomisation were well matched (table 1). The 
median age at entry was 36 years (range 30 to 44 years); 79% of entrants were parous. The most 
frequent past medical problems were gynaecologic, five (13%) in the T-arm and six (16%) in the 
C-arm.  Six subjects had previous breast biopsies, all of which were benign. All women had at 
least 2 relatives with breast cancer (table 2).  
Primary endpoint – adherence 
 
Of the 38 participants in the T-arm, 20 completed the two year treatment period and of the 37 
women in the C-arm, 27 completed treatment (Figure 1). Reasons for non-adherence in the T-
arm were side effects in 13 (all vasomotor symptoms or mood disorders), three wished to have 
risk reducing surgery, one stopped treatment to become pregnant and one was lost to follow 
up. Of the 10 women who did not complete observation, four elected for risk reducing surgery, 
two wished to take tamoxifen, one developed breast cancer, one became pregnant and two 
were lost to follow up. Of the 38 subjects in the T-arm, ten (26%) completed the 24 month 
schedule with no deviations.  A further ten (26%) had some deviations but continued on to 
complete the 24 months.  The reasons for deviation ranged from simply forgetting to take a few 
tablets, stopping to go on holiday or delaying because of operations. 
Secondary end points 
Side Effects/Quality of Life 
The number of women completing evaluable questionnaires (ES, SAQ, STAI and CWS) at each 
time point ranged from 61-100% (Table S1). There were no appreciable differences between the 
overall scores at baseline between the two arms of the study (Table S2) 
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ES (Endocrine Symptoms) 
The ES questionnaire captures the severity of 20 of the most common symptoms associated 
with endocrine therapy.  The ES score decreased (i.e. women experienced more severe 
problems) from baseline to month 3 onwards in T-arm, but significantly only by the 12 month 
time point (p=0.01). The range for T-arm was <23,72> and for (C) was <40,72>, (Figure 2A). The 
major toxicity was the expected large increase in vasomotor symptoms (hot flushes, cold sweats 
and night sweats) (Figure 2B). All other symptoms were highly variable between T-arm and C-
arm, but weight gain and headaches were prominent in T-arm (Figures 1S, 2S and 3S). 
Effects on Sexual Activity:  At baseline, 33/37 (89%) in the T-arm and 32/36 (89%) in the C-arm 
were married or having an intimate relationship.  Pleasure was significantly decreased and 
discomfort significantly increased in the T-arm (Figure 2C and 2D).  
Anxiety/worry scores: There was no significant change in trait (Table 3S) or state anxiety (Figure 
2E). There was significantly less cancer worry in T-arm at 3, 6 and 12 months from baseline 
(Figure 2F).  
Lipids 
There were no significant changes in serum lipids between the two arms of the trial. 
 
Bone density  
Bone density measurements were made in the T-arm only. We report the nine women who had 
measurements at the appropriate times at baseline, one year and at the end of study at two 
years (Supplementary Table). There were small decreases between from baseline after two 
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years for DXA measures of the lumbar spine (P=0.015) and total hip (P=0.011) but no significant 
change for femoral neck (P=0.11). Medians and ranges are used because of the small number of 
subjects. There was a highly significant decline in all measures at year one, with some recovery 
during year two. The reduction of bone in the lumbar spine was 10.9% by year one but some 
recovery occurred during year 2 (7.0%). Four women became osteopaenic (t-score <-1.0) in the 
lumbar spine at the end of year one and two remained osteopaenic by year two. During the 
study, four subjects developed fractures, three in T-arm (tibia at six months, metatarsal at six 
months and metatarsal at 13 months) and 1 in C-arm (scaphoid at 24 months). 
Sixty-one subjects had at least two serum measures of CTX and 53 had between 3 and 5 
measurements over two years. CTX for the T-arm rose significantly from median of 1168 pmol/L 
to 2831 pmol/L over the first six months (p<0.005) and remained significantly higher at 12 
months returning to a median of 1342 pmol/L at 18 months.  This was not the case for the C-
arm where the median stayed reasonably stable over the 18 months between 1000 pmol/L and 
1500 pmol/L, thus giving a significant difference between the arms at both 6 and 12 months 
(p<0.005).  
Mammographic density  
 
Percent density was assessed by two readers using a visual analogue scale. The Spearman 
correlation between the two readers was 0.93 (Figure 1A). Mammograms were available for 
both T- and C-arms at baseline, during (Year 1 and 2) and after treatment (Year 3 and 4); 58 of 
the 67 women entered in Manchester had 2 or more mammograms available (2 n=11, 3 n=15, 4 
n=20 and 5 n=10)). Inspection of the data suggested that there was a decline in breast density 
during treatment which tended to return to baseline after cessation of treatment (Figure 1B).  
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We first compared change in density over four years in 22 subjects (13 treatment, 9 control) 
who had all four mammograms at baseline and years 1, 2 and 3. In C-arm there was a slight 
linear decline in mean density, whereas in the T-arm there was a steeper decline of density 
during treatment and an increase when treatment was stopped after 2 years.  
We then considered all subjects with density measurements (Figure 3). Mean breast density 
during years 1 and 2 was compared with that before and after treatment (baseline and years 3 
and 4) (Figure 3C). During the treatment period (years 1 and 2) there was a 4.7% (95% CI 0.9 - 
8.7%) reduction of mean density in the T-arm, but  a non-significant difference in c-arm (mean 
density increase 2.0% (95% CI -2.3 to 6.4%)).  The density reduction in the T arm was particularly 
marked in younger women (Figure 2D).  A repeated measures statistical model indicated that 
both the treatment effect on density (P=0.0003) and age (P=0.0013) were important 
(supplementary table). 
The median duration of follow up in the study is 9 years. There have been two Invasive and two 
DCIS cancers in the control arm and one Invasive and one DCIS in the T-arm. These arose at 19, 
22, 30 and 48 months from baseline in C-arm and 36 and 43 months in T-arm.  
 
Discussion  
 
We report a randomised trial of ovarian suppression and raloxifene and screening versus 
screening alone. Both uptake of randomization and subsequent adherence were low. Quality of 
life was largely maintained in those who completed treatment, but patients in the T-arm 
experienced severe vasomotor complaints, and decreased pleasure and more discomfort from 
sexual activity. At the exit interview 9 of 23 patients in the T-arm said that they would not 
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consider the option of further treatment for 5 years because of the side-effects. There were no 
significant changes in serum lipids.  Treatment was associated with reduced bone density and 
mammographic density. 
 
Uptake was approximately 7.5% of all women approached. In the sub-group at particularly high 
risk (≥40% lifetime risk) recruited on the initial protocol, the uptake was 5.3%. The overall 
uptake of 7.5% is similar to the companion GISS randomised trial in Germany;  31 women were 
randomized out of 322 approached (9.6%) (14). In the trial reported by Spicer et al (1993)(12),   
21 women at high-risk were recruited, but the number approached was not reported, nor in a 
subsequent study of 9 subjects with BRCA1/2 mutations (13). In prevention studies using 
tamoxifen in the same clinic we find that uptake averages about 10-12% (23,24). In an overview 
of all tamoxifen prevention trials/studies the uptake varied between 0.08 and 42% depending 
on the type of recruitment and centre (24).  
 
Fifty two percent of women competed the two year treatment period which compares with 66% 
in the GISS-Study. The main reason for non-completion was toxicity in 33% of RAZOR patients 
but none of the 15 women on treatment dropped out for this reason in the GISS study (14). A 
number of women wished to opt-out and undertake risk-reducing breast surgery (four in each 
arm) and a wish of two women in C arm begin tamoxifen reduced compliance in the control T-
arm to  73%. Thus in women at high-risk in prevention trials there is attrition not only because 
of toxicity, but also the wish to have proven treatments such as surgery or chemoprevention. 
The drop-out rate of 48% at two years compared unfavourably with trials of SERMs and 
aromatase inhibitors, where the estimated drop-out two years into these studies is 
approximately 20-30% (25, 26). It is of interest that there were practically no reported drop-outs 
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over a two-year period in two trials of LHRH agonists and add-back oestrogen to control 
vasomotor symptoms (12, 13). 
 
Toxicity of the interventions was measured using an specially developed and validated scale for 
women having endocrine therapy (Endocrine Subscale [ES])(16,27). It consisted of twenty of the 
most frequent toxicities reported by women on therapy. As expected there was a significant 
change in symptoms in both the RAZOR and GISS trials. Virtually all women on treatment had 
marked vasomotor symptoms as is also seen post oophorectomy and other studies of LHRH 
analogues given for breast cancer treatment (Figure 2B) (28,10). Symptoms other than 
vasomotor were uncommon but included weight gain and headaches. With the exception of the 
brief periods of hot flushes or vaginal dryness, which were eliminated by increasing the dose of 
CE, subjects in the two trials of add-back sex steroids were reported to have minimal symptoms.  
 
The Sexual Activity Questionnaire (SAQ) was developed to investigate the impact of long-term 
tamoxifen on the sexual functioning of women at high-risk of developing breast cancer (17). The 
SAQ was first assessed in women in the general population and  in women at increased risk of 
breast cancer where acceptability was equally high and no difference was found between 
women at high risk and population controls. The majority of variance in sexual functioning can 
be explained by three factors: pleasure from sexual intercourse, discomfort during sexual 
intercourse and habit.  We found a significant reduction in sexual pleasure and an increase in 
discomfort during intercourse in treated women in the RAZOR trial and this was also noted in 
GISS study. Studies after oophorectomy in BRCA1/2 carriers have reported similar results (29, 
30, 31). The use of HRT appears to reduce discomfort but not improve reduction in pleasure (31, 
32) which may be helped by add-back androgens (35, 12, 13). There were no significant 
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differences in scores for pleasure or discomfort over this treatment time period. Since studies 
have shown little difference in sexual activity between use of raloxifene and control, albeit in 
postmenopausal women, we assume that the reduction in pleasure and increase in discomfort 
found in this study reflect the effect of goserelin (36).   
 
There were no significant differences in state or trait anxiety between the two arms of the study 
but a significant reduction in the CWS in T-arm.  The CWS was also reduced after prophylactic 
oophorectomy in women with BRCA1/2 mutations who were at high risk of ovarian cancer (29, 
37). Only 3 women in RAZOR had a BRCA1/2 mutation and thus the majority were not at known 
elevated risk of ovarian carcinoma and suggests that CWS is also reduced for perceived breast 
cancer risk reduction. 
Bone mineral density did not decline in the GISS study where add-back ibandronate was used. In 
RAZOR we were testing whether add-back raloxifene might maintain bone density. However, at 
one year there was a loss of 10.7% of bone in the lumber spine which is more than in studies 
post bilateral oophorectomy, where losses of 6.7%  (38) and 3.0% (39) were reported. However 
there was a rise in bone density in the second year which may have been a delayed effect of 
raloxifene. In premenopausal women treated with goserelin after surgery for breast cancer, 
tamoxifen was not associated with preservation of bone density. At three years the loss in the 
lumber spine was 11.6% (40). It is of interest that add-back treatment with oestrogen and 
testosterone was effective in preserving bone density in the studies of Spicer et al. (1993) (12) 
and Weitzel et al. (2007) (13), and this has also been reported in a study of the treatment of 
endometriosis with the LHRH agonist Desorelin (41). It is important to maintain bone density not 
only to reduce fracture risk but observational studies suggest that early menopause affects long 
term survival if hormone replacement therapy is not used (31, 42, 43).  
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Mammographic density was shown to be reduced In the Spicer and Wietzel studies (12, 13) 
using various measures. In the study reported here, percentage mammographic density was 
estimated by two expert radiologists with good correlation between the two readers. The main 
result was that, in agreement with the Californian studies, we demonstrated a significant 
reduction in density and a recovery of density after treatment was stopped at two years. 
Visually assessed density is also reduced after treatment with tamoxifen and may be an 
indication of responsiveness to the effectiveness of tamoxifen as a preventive agent (44).  
The strengths of this study are that we have a clear indication that, even in women at high risk, 
ovarian suppression is not likely to be acceptable as a preventive option based on low uptake for 
treatment and subsequent poor adherence. Furthermore, the magnitude of any reduction in 
breast cancer risk following bilateral oophorectomy in BRCA1 mutation carriers has recently 
been questioned (6, 7). The poor adherence is due not only to vasomotor side effects but also to 
the perceived need for surgical prophylaxis in this group of women at particularly high risk. The 
limitations of the study include the failure to enter 80 women as planned and small numbers 
upon which we base comments on the effect of treatment on bone and mammographic density. 
In the modest number of women that maintained treatment side-effects were as expected less 
severe or better tolerated, but prospectively identifying those as a target population would be 
very difficult.  
In conclusion, treatment with goserelin and raloxifene, as a nonsurgical option for breast cancer 
prevention, was shown to have low uptake and adherence and thus, in its current form, is not 
likely to be widely accepted, even if effective. Uptake is lower compared with many studies 
using tamoxifen (24). Other measures than raloxifene may be necessary to maintain bone 
density and it remains to be demonstrated that short term mammographic density reduction is 
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beneficial. Trials aimed at chemoprevention in healthy women at high cancer risk may benefit 
from the involving patients to improve the selection of acceptable intervention strategies and 
the design of information, physician training and study support materials aimed at improving 
recruitment and retention. The safety of ovarian suppression with add-back oestrogen and 
testosterone might be explored in future longer duration prevention trials.  
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Table 1.  Baseline characteristics of women randomised 
 
 
 
N 
Goserelin + ral. 
 + screening 
n=38  
Screening only  
n=37  
Age Median 
Range 
36 
<30, 44> 
36 
<30, 44> 
Age at menarche Median 
Range 
13 
<11, 16> 
12 
<9, 15> 
Parous No 
Yes 
10 (26) 
28 (74) 
6 (16) 
31 (84) 
Smoking history Never 
Current 
Ex 
22 (58) 
11 (29) 
  5 (13) 
15 (41) 
14 (38) 
  8 (21) 
Past medical history Cardiac 
Cancer 
Diabetes 
Thrombosis 
Eye problems 
Osteoporosis 
Gynaecological 
diseases 
2 (5) 
- 
1 (3) 
1 (3) 
- 
- 
5 (13) 
- 
- 
- 
- 
- 
1 (3) 
6 (16) 
Previous  oral 
contraceptive 
use 
None 3 (8) 3 (8) 
Breast biopsy (benign) Yes 4 (11) 2 (5) 
 
 
 
 
 
 
 
 
 
 
  
Table 2. Breast cancer risk categories at the beginning of the study 
 
Risk Category present 
 
Goserelin+ral. 
+ screening  
      n=38  
Screening 
only 
 n=37  
BRCA-1 germ-line mutation  1 (3) 
BRCA-2 germ-line mutation  2 (5) 
First degree relative known to carry the BRCA1/BRCA2 
mutation 
 2 (5) 
First degree female relative diagnosed with breast 
cancer below the age of 40 
11 (29) 15 (41) 
First degree female relative with bilateral breast cancer, 
with first cancer diagnosed before age 50 
4 (11) 3 (8) 
Two first degree or one first and one second degree 
female relative from the same side of the family, both 
diagnosed with breast cancer before age 60. 
22 (58) 22 (59) 
Two first degree or one first and one second degree 
female relatives, both diagnosed with breast cancer 
before age 60 and ovarian cancer at any age 
1 (3) 1 (3) 
One first and one second degree female relative with 
breast and ovarian cancer diagnosed before age 60 
36 (95) 36 (97) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure legends 
 
Figure 1.  Consort flow diagram of numbers approached and study participants 
 
Figure 2 Results from toxicity/quality of life measures. Treated in blue and control in pink. A 
Endocrine Symptom scale all 16 measures. B Endocrine Symptom scale vasomotor 
symptoms of 3 an 4 severity. C Sexual Activity Questionnaire – pleasure. D Sexual Activity 
Questionnaire – discomfort. E State Anxiety Score.  Cancer Worry Scale. (The numbers of 
women at each time point for all measures are shown in table S1). F Median cancer worry 
scores. 
 
Figure 3 A.. Mean density change (VAS from two readers; o control, triangle treatment, | 
standard error) in women who had yearly mammograms available from baseline to year 3 . 
B. Reduction in mean density  from years 1 and 2 (o control, triangle treatment) compared 
with baseline and years 3,4:  C.  
Younger women were more likely to see a change in density: VAS difference (mean VAS in 
years 1&2 minus mean VAS at baseline and years 
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(n=~1,000) 
Declined to participate (n= 925) 
  
Analysed  (n=38) 
Excluded from analysis (n= 0) 
Discontinued intervention (n=18) 
Reasons 13 side effects, 2 prophylactic 
mastectomy, 1 BSOH, 1 pregnancy, 1 emigration  
  
Allocated to intervention (n=38)  
Goserelin + raloxifene + screening 
Completed allocated intervention (n=20) 
  
Discontinued intervention (n=10) 
Reasons 1 prophylactic mastectomy, 3 BSOH, 
2 other treatments, 1 breast cancer, 1 
pregnancy, 1 lost to follow up, 1 emigration  
Allocated to intervention (n=37) 
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Completed  allocated intervention (n=27) 
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Excluded from analysis(n=0) 
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